Therapeutics targeting Nogo-A hold promise for stroke restoration

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 200-208

  Kumar, Prateek ^a   Moon, Lawrence D F ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antibodies; Cerebral ischemia; Neurorestoration; Nogo; Plasticity; Stroke

Indexed keywords

MESSENGER RNA; NOGO A ANTIBODY; PROTEIN NOGO A;

AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; EXPERIMENTAL MODEL; FORELIMB; HYPOXIA; MEMORY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOVEMENT (PHYSIOLOGY); NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NONHUMAN; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN STRUCTURE; REHABILITATION CARE; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; MYELIN PROTEINS; RECEPTORS, CELL SURFACE; STROKE;

EID: 84876701776     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312020006     Document Type: Article

References (97)

1. Aho, K.; Harmsen, P.; Hatano, S.; Marquardsen, J.; Smirnov, V.E.; Strasser, T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull. World Health Org., 1980, 58, 113-130.
2. Murray, C.J.; Lopez, A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349, 1269-1276.
3. Bonita, R. Epidemiology of stroke. Lancet, 1992, 339, 342-344.
4. Truelsen, T.; Piechowski-Jozwiak, B.; Bonita, R.; Mathers, C.; Bogousslavsky, J.; Boysen, G. Stroke incidence and prevalence in Europe: a review of available data. Eur. J. Neurol., 2006, 13, 581-598.
5. Murray, C.J.; Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997, 349, 1436-1442.
6. Lopez, A.D.; Mathers, C.D.; Ezzati, M.; Jamison, D.T.; Murray, C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 2006, 367, 1747-1757.
7. Saka, O.; McGuire, A.; Wolfe, C. Cost of stroke in the United Kingdom. Age Ageing, 2009, 38, 27-32.
8. Dewey, H.M.; Thrift, A.G.; Mihalopoulos, C.; Carter, R.; Macdonell, R.A.; McNeil, J.J.; Donnan, G.A. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke, 2001, 32, 2409-2416.
9. Rothwell, P.M. The high cost of not funding stroke research: a comparison with heart disease and cancer, Lancet, 2001, 357, 1612-1616.
10. Donnan, G.A.; Fisher, M.; Macleod, M.; Davis, S.M. Stroke. Lancet, 2008, 371, 1612-1623.
11. Barsan, W.G.; Brott, T.G.; Broderick, J.P.; Haley, E.C.; Levy, D.E.; Marler, J.R. Time of hospital presentation in patients with acute stroke. Arch. Int. Med., 1993, 153, 2558-2561.
12. Kothari, R.; Jauch, E.; Broderick, J.; Brott, T.; Sauerbeck, L.; Khoury, J.; Liu, T. Acute stroke: delays to presentation and emergency department evaluation. Ann. Emerg. Med., 1999, 33, 3-8.
13. Fang, J.; Yan, W.; Jiang, G.X.; Li, W.; Cheng, Q. Time interval between stroke onset and hospital arrival in acute ischemic stroke patients in Shanghai, China. Clin. Neurol. Neurosurg., 2011, 113, 85-88.
14. Agyeman, O.; Nedeltchev, K.; Arnold, M.; Fischer, U.; Remonda, L.; Isenegger, J.; Schroth, G.; Mattle, H.P. Time to admission in acute ischemic stroke and transient ischemic attack. Stroke, 2006, 37, 963-966.
15. Evenson, K.R.; Foraker, R.E.; Morris, D.L.; Rosamond, W.D. A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int. J. Stroke, 2009, 4, 187-199.
16. Azzimondi, G.; Bassein, L.; Fiorani, L.; Nonino, F.; Montaguti, U.; Celin, D.; Re, G.; D'Alessandro, R. Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment. Stroke, 1997, 28, 537-542.
17. Cheng, Y.D.; Al-Khoury, L.; Zivin, J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx J. Am. Soc. Exp. NeuroTher., 2004, 1, 36-45.
18. Savitz, S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol., 2007, 205, 20-25.
19. Ginsberg, M.D. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke, 2007, 38, 1967-1972.
20. Faden, A.I.; Stoica, B. Neuroprotection: challenges and opportunities. Arch. Neurol., 2007, 64, 794-800.
21. Young, A.R.; Ali, C.; Duretete, A.; Vivien, D. Neuroprotection and stroke: time for a compromise. J. Neurochem., 2007, 103, 1302-1309.
22. Savitz, S.I.; Fisher, M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann. Neurol., 2007, 61, 396-402.
23. The bitterest pill. Nature, 2006, 444, 532-533.
24. Soleman, S.; Yip, P.K.; Duricki, D.A.; Moon, L.D. Delayed treatment with chondroitinase ABC promotes sensorimotor recovery and plasticity after stroke in aged rats. Brain, 2012, 135, 1210-1223.
25. Chen, M.S.; Huber, A.B.; van der Haar, M.E.; Frank, M.; Schnell, L.; Spillmann, A.A.; Christ, F.; Schwab, M.E. Nogo-A is a myelinassociated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature, 2000, 403, 434-439.
26. GrandPre, T.; Li, S.; Strittmatter, S.M. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature, 2002, 417, 547-551.
27. Prinjha, R.; Moore, S.E.; Vinson, M.; Blake, S.; Morrow, R.; Christie, G.; Michalovich, D.; Simmons, D.L.; Walsh, F.S. Inhibitor of neurite outgrowth in humans. Nature, 2000, 403, 383-384.
28. Wang, X.; Chun, S.J.; Treloar, H.; Vartanian, T.; Greer, C.A.; Strittmatter, S.M. Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J. Neurosci., 2002, 22, 5505-5515.
29. Schwab, M.E. Nogo and axon regeneration. Curr. Opin. Neurobiol., 2004, 14, 118-124.
30. Barrette, B.; Vallieres, N.; Dube, M.; Lacroix, S. Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol. Cell Neurosci., 2007.
31. Oertle, T.; van der Haar, M.E.; Bandtlow, C.E.; Robeva, A.; Burfeind, P.; Buss, A.; Huber, A.B.; Simonen, M.; Schnell, L.; Brosamle, C.; Kaupmann, K.; Vallon, R.; Schwab, M.E. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J. Neurosci., 2003, 23, 5393-5406.
32. Fournier, A.E.; GrandPre, T.; Strittmatter, S.M. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature, 2001, 409, 341-346.
33. Schweigreiter, R.; Walmsley, A.R.; Niederost, B.; Zimmermann, D.R.; Oertle, T.; Casademunt, E.; Frentzel, S.; Dechant, G.; Mir, A.; Bandtlow, C.E. Versican V2 and the central inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent pathways that converge at RhoA. Mol. Cell. Neurosci., 2004, 27, 163-174.
34. Wang, H.; Yao, Y.; Jiang, X.; Chen, D.; Xiong, Y.; Mu, D. Expression of Nogo-A and NgR in the developing rat brain after hypoxia-ischemia. Brain Res., 2006, 1114, 212-220.
35. Zhou, C.; Li, Y.; Nanda, A.; Zhang, J.H. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem Biophys. Res. Commun., 2003, 309, 368-376.
36. Jiang, W.; Xia, F.; Han, J.; Wang, J. Patterns of Nogo-A, NgR, and RhoA expression in the brain tissues of rats with focal cerebral infarction. Transl. Res. J. Lab.Clin. Med., 2009, 154, 40-48.
37. Cheatwood, J.L.; Emerick, A.J.; Schwab, M.E.; Kartje, G.L. Nogo-A expression after focal ischemic stroke in the adult rat. Stroke, 2008, 39, 2091-2098.
38. Trifunovski, A.; Josephson, A.; Bickford, P.C.; Olson, L.; Brene, S. Selective decline of Nogo mRNA in the aging brain. Neuroreport, 2006, 17, 913-916.
39. Li, S.; Carmichael, S.T. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol. Dis., 2006, 23, 362-373.
40. Eslamboli, A.; Grundy, R.I.; Irving, E.A. Time-dependent increase in Nogo-A expression after focal cerebral ischemia in marmoset monkeys. Neurosci. Lett., 2006, 408, 89-93.
41. Josephson, A.; Trifunovski, A.; Widmer, H.R.; Widenfalk, J.; Olson, L.; Spenger, C. Nogo-receptor gene activity: cellular localization and developmental regulation of mRNA in mice and humans. J. Comp. Neurol., 2002, 453, 292-304.
42. Josephson, A.; Widenfalk, J.; Widmer, H.W.; Olson, L.; Spenger, C. Nogo mRNA expression in adult and fetal human and rat nervous tissue and in weight drop injury. Exp. Neurol., 2001, 169, 319-328.
43. O'Neill, P.; Whalley, K.; Ferretti, P. Nogo and Nogo-66 receptor in human and chick: implications for development and regeneration. Dev. Dyn., 2004, 231, 109-121.
44. Satoh, J.; Onoue, H.; Arima, K.; Yamamura, T. Nogo-A and Nogo receptor expression in demyelinating lesions of multiple sclerosis. J. Neuropathol. Exp. Neurol., 2005, 64, 129-138.
45. Buss, A.; Pech, K.; Merkler, D.; Kakulas, B.A.; Martin, D.; Schoenen, J.; Noth, J.; Schwab, M.E.; Brook, G.A. Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord. Brain, 2005, 128, 356-364.
46. Zorner, B.; Schwab, M.E. Anti-Nogo on the go: from animal models to a clinical trial. Ann. NY Acad. Sci., 2010, 1198(Suppl 1), E22-E34.
47. Papadopoulos, C.M.; Tsai, S.Y.; Alsbiei, T.; O'Brien, T.E.; Schwab, M.E.; Kartje, G.L. Functional recovery and neuroanatomical plasticity following middle cerebral artery occlusion and IN-1 antibody treatment in the adult rat. Ann. Neurol., 2002, 51, 433-441.
48. Whishaw, I.Q.; Gorny, B.; Sarna, J. Paw and limb use in skilled and spontaneous reaching after pyramidal tract, red nucleus and combined lesions in the rat: behavioral and anatomical dissociations. Behav. Brain Res., 1998, 93, 167-183.
49. Zaaimi, B.; Edgley, S.A.; Soteropoulos, D.S.; Baker, S.N. Changes in descending motor pathway connectivity after corticospinal tract lesion in macaque monkey. Brain, 2012, 135, 2277-2289.
50. Sasaki, S.; Isa, T.; Pettersson, L.G.; Alstermark, B.; Naito, K.; Yoshimura, K.; Seki, K.; Ohki, Y. Dexterous finger movements in primate without monosynaptic corticomotoneuronal excitation. J. Neurophysiol., 2004, 92, 3142-3147.
51. Alstermark, B.; Pettersson, L.G.; Nishimura, Y.; Yoshino-Saito, K.; Tsuboi, F.; Takahashi, M.; Isa, T. Motor command for precision grip in the macaque monkey can be mediated by spinal interneurons. J. Neurophysiol., 2011, 106, 122-126.
52. Z'Graggen, W.J.; Metz, G.A.; Kartje, G.L.; Thallmair, M.; Schwab, M.E. Functional recovery and enhanced corticofugal plasticity after unilateral pyramidal tract lesion and blockade of myelin-associated neurite growth inhibitors in adult rats. J. Neurosci., 1998, 18, 4744-4757.
53. Thallmair, M.; Metz, G.A. S.; Z'Graggen, W.J.; Raineteau, O.; Kaitje, G.L.; Schwab, M.E. Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. Nat. Neurosci., 1998, 1, 124-131.
54. Wiessner, C.; Bareyre, F.M.; Allegrini, P.R.; Mir, A.K.; Frentzel, S.; Zurini, M.; Schnell, L.; Oertle, T.; Schwab, M.E. Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J. Cereb. Blood Flow Metab., 2003, 23, 154-165.
55. Barone, F.C.; Clark, R.K.; Price, W.J.; White, R.F.; Feuerstein, G.Z.; Storer, B.L.; Ohlstein, E.H. Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res., 1993, 623, 77-82.
56. Seymour, A.B.; Andrews, E.M.; Tsai, S.Y.; Markus, T.M.; Bollnow, M.R.; Brenneman, M.M.; O'Brien, T.E.; Castro, A.J.; Schwab, M.E.; Kartje, G.L. Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats. J. Cereb. Blood Flow Metab., 2005, 25, 1366-1375.
57. Tsai, S.Y.; Papadopoulos, C.M.; Schwab, M.E.; Kartje, G.L. Delayed anti-Nogo A therapy improves function after chronic stroke in adult rats. Stroke, 2011, 42, 186-190.
58. Markus, T.M.; Tsai, S.Y.; Bollnow, M.R.; Farrer, R.G.; O'Brien, T.E.; Kindler-Baumann, D.R.; Rausch, M.; Rudin, M.; Wiessner, C.; Mir, A.K.; Schwab, M.E.; Kartje, G.L. Recovery and brain reorganization after stroke in adult and aged rats. Ann. Neurol., 2005, 58, 950-953.
59. Gillani, R.L.; Tsai, S.Y.; Wallace, D.G.; O'Brien, T.E.; Arhebamen, E.; Tole, M.; Schwab, M.E.; Kartje, G.L. Cognitive recovery in the aged rat after stroke and anti-Nogo-A immunotherapy. Behav. Brain Res., 2010, 208, 415-424.
60. Brenneman, M.M.; Wagner, S.J.; Cheatwood, J.L.; Heldt, S.A.; Corwin, J.V.; Reep, R.L.; Kartje, G.L.; Mir, A.K.; Schwab, M.E. Nogo-A inhibition induces recovery from neglect in rats. Behav. Brain Res., 2008, 187, 262-272.
61. Tsai, S.Y.; Markus, T.M.; Andrews, E.M.; Cheatwood, J.L.; Emerick, A.J.; Mir, A.K.; Schwab, M.E.; Kartje, G.L. Intrathecal treatment with anti-Nogo-A antibody improves functional recovery in adult rats after stroke. Exp. Brain Res., 2007, 182, 261-266.
62. Kilic, E.; ElAli, A.; Kilic, U.; Guo, Z.; Ugur, M.; Uslu, U.; Bassetti, C.L.; Schwab, M.E.; Hermann, D.M. Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J. Cereb. Blood Flow Metab., 2010, 30, 969-984.
63. Sena, E.S.; van der Worp, H.B.; Bath, P.M.; Howells, D.W.; Macleod, M.R. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol., 2010, 8, e1000344.
64. Lee, J.K.; Kim, J.E.; Sivula, M.; Strittmatter, S.M. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J. Neurosci., 2004, 24, 6209-6217.
65. Filbin, M.T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci., 2003, 4, 703-713.
66. Wang, T.; Wang, J.; Yin, C.; Liu, R.; Zhang, J.H.; Qin, X. Downregulation of Nogo receptor promotes functional recovery by enhancing axonal connectivity after experimental stroke in rats. Brain Res., 2010, 1360, 147-158.
67. Caroni, P.; Schwab, M.E. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron, 1988, 1, 85-96.
68. Zagrebelsky, M.; Buffo, A.; Skerra, A.; Schwab, M.E.; Strata, P.; Rossi, F. Retrograde regulation of growth-associated gene expression in adult rat Purkinje cells by myelin-associated neurite growth inhibitory proteins. J. Neurosci., 1998, 18, 7912-7929.
69. Huber, A.B.; Schwab, M.E. Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol. Chem., 2000, 381, 407-419.
70. Naus, C.G.; Flumerfelt, B.A.; Hrycyshyn, A.W. An HRP-TMB ultrastructural study of rubral afferents in the rat. J. Comp. Neurol. 1985, 239, 453-465.
71. Kuchler, M.; Fouad, K.; Weinmann, O.; Schwab, M.E.; Raineteau, O. Red nucleus projections to distinct motor neuron pools in the rat spinal cord. J. Comp. Neurol., 2002, 448, 349-359.
72. Raineteau, O.; Fouad, K.; Bareyre, F.M.; Schwab, M.E. Reorganization of descending motor tracts in the rat spinal cord. Eur. J. Neurosci., 2002, 16, 1761-1771.
73. Kartje, G.L.; Schulz, M.K.; Lopez-Yunez, A.; Schnell, L.; Schwab, M.E. Corticostriatal plasticity is restricted by myelin-associated neurite growth inhibitors in the adult rat. Ann. Neurol., 1999, 45, 778-786.
74. Wenk, C.A.; Thallmair, M.; Kartje, G.L.; Schwab, M.E. Increased corticofugal plasticity after unilateral cortical lesions combined with neutralization of the IN-1 antigen in adult rats. J. Comp. Neurol., 1999, 410, 143-157.
75. Napieralski, J.A.; Butler, A.K.; Chesselet, M.F. Anatomical and functional evidence for lesion-specific sprouting of corticostriatal input in the adult rat. J. Comp. Neurol., 1996, 373, 484-497.
76. D'Hooge, R.; De Deyn, P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Brain Res. Rev., 2001, 36, 60-90.
77. Knierim, J.J. Neural representations of location outside the hippocampus. Learn. Mem., 2006, 13, 405-415.
78. Cadelli, D.; Schwab, M.E. Regeneration of Lesioned Septohippocampal Acetylcholinesterase-positive Axons is Improved by Antibodies Against the Myelin-associated Neurite Growth Inhibitors NI-35/250. Eur. J. Neurosci., 1991, 3, 825-832.
79. Reep, R.L.; Corwin, J.V.; Cheatwood, J.L.; Van Vleet, T.M.; Heilman, K.M.; Watson, R.T. A rodent model for investigating the neurobiology of contralateral neglect. Cogn. Behav. Neurol., 2004, 17, 191-194.
80. Kolb, B.; Gibb, R.; van der Kooy, D. Cortical and striatal structure and connectivity are altered by neonatal hemidecortication in rats. J. Comp. Neurol., 1992, 322, 311-324.
81. Yu, X.H.; Moret, V.; Rouiller, E.M. Re-examination of the plasticity of the corticothalamic projection after unilateral neonatal lesion of the sensorimotor cortex in the rat: a phaseolus vulgarisleucoagglutinin tracing study. J. Hirnforschung, 1995, 36, 123-133.
82. Leong, S.K.; Lund, R.D. Anomalous bilateral corticofugal pathways in albino rats after neonatal lesions. Brain Res., 1973, 62, 218-221.
83. Castro, A.J.; Mihailoff, G.A. Corticopontine remodelling after cortical and/or cerebellar lesions in newborn rats. J. Comp. Neurol., 1983, 219, 112-123.
84. Castro, A.J. Ipsilateral corticospinal projections after large lesions of the cerebral hemisphere in neonatal rats. Exp. Neurol., 1975, 46, 1-8.
85. Emerick, A.J.; Neafsey, E.J.; Schwab, M.E.; Kartje, G.L. Functional reorganization of the motor cortex in adult rats after cortical lesion and treatment with monoclonal antibody IN-1. J. Neurosci., 2003, 23, 4826-4830.
86. Maier, I.C.; Ichiyama, R.M.; Courtine, G.; Schnell, L.; Lavrov, I.; Edgerton, V.R.; Schwab, M.E. Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury. Brain, 2009, 132, 1426-1440.
87. Maier, I.C.; Baumann, K.; Thallmair, M.; Weinmann, O.; Scholl, J.; Schwab, M.E. Constraint-induced movement therapy in the adult rat after unilateral corticospinal tract injury. J. Neurosci., 2008, 28, 9386-9403.
88. Biernaskie, J.; Corbett, D. Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. J. Neurosci., 2001, 21, 5272-5280.
89. Kilkenny, C.; Browne, W.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Animal research: reporting in vivo experiments-The ARRIVE Guidelines. J. Cereb. Blood Flow Metab., 2011.
90. Kilkenny, C.; Parsons, N.; Kadyszewski, E.; Festing, M.F.; Cuthill, I.C.; Fry, D.; Hutton, J.; Altman, D.G. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS ONE, 2009, 4, e7824.
91. Kilkenny, C.; Browne, W.J.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol., 2010, 8, e1000412.
92. Fouad, K.; Klusman, I.; Schwab, M.E. Regenerating corticospinal fibers in the Marmoset (Callitrix jacchus) after spinal cord lesion and treatment with the anti-Nogo-A antibody IN-1. Eur. J. Neurosci., 2004, 20, 2479-2482.
93. Freund, P.; Schmidlin, E.; Wannier, T.; Bloch, J.; Mir, A.; Schwab, M.E.; Rouiller, E.M. Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates-re-examination and extension of behavioral data. Eur. J. Neurosci., 2009, 29, 983-996.
94. Freund, P.; Wannier, T.; Schmidlin, E.; Bloch, J.; Mir, A.; Schwab, M.E.; Rouiller, E.M. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J. Comp. Neurol., 2007, 502, 644-659.
95. Freund, P.; Schmidlin, E.; Wannier, T.; Bloch, J.; Mir, A.; Schwab, M.E.; Rouiller, E.M. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat. Med., 2006, 12, 790-792.
96. Tuszynski, M. Challenges to the report of Nogo antibody effects in primates. Nat. Med., 2006, 12, 1231-1232; author reply 1232-1233.
97. Ho, C.; Tessier-Lavigne, M. Challenges to the report of Nogo antibody effects in primates. Nat. Med., 2006, 12, 1232; author reply 1232-1233.